TY  - JOUR
AU  - Antonijević, Nebojša
AU  - Mitrović, Predrag
AU  - Gošnjić, Nikola
AU  - Orlić, Dejan
AU  - Kadija, Saša
AU  - Ilić Mostić, Tanja
AU  - Savić, Nebojša
AU  - Birovljev, Ljubica
AU  - Leković, Žaklina
AU  - Matić, Dragan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5079
AB  - Caesarean section is a challenging intervention in patients treated with dual antiplatelet therapy. We present a case of a 32-year-old pregnant woman experiencing large acute myocardial infarction (MI) of the anterolateral wall, complicated by cardiogenic shock in the 38th week of pregnancy, and treated with drug-eluting stent implantation and dual antiplatelet therapy (DAPT) consisting of aspirin and ticagrelor. Less than 24 h after the MI delivery started, an urgent Caesarean section was indicated. As multiplate aggregometry testing showed a relatively insufficient level of ticagrelor platelet inhibition and a moderate level of aspirin platelet inhibition, a Caesarean section was performed without discontinuation of ticagrelor, which was decided due to the need for emergency surgery. Local hemostatic measures including administration of tranexamic acid were applied. The patient did not experience excessive bleeding. A healthy male baby was born. To the best of our knowledge, this is the first reported case of surgery in pregnant women treated with DAPT without ticagrelor discontinuation.
PB  - MDPI
T2  - Journal of Personalized Medicine
T1  - Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention
VL  - 13
IS  - 9
DO  - 10.3390/jpm13091344
ER  - 

@article{
author = "Antonijević, Nebojša and Mitrović, Predrag and Gošnjić, Nikola and Orlić, Dejan and Kadija, Saša and Ilić Mostić, Tanja and Savić, Nebojša and Birovljev, Ljubica and Leković, Žaklina and Matić, Dragan",
year = "2023",
abstract = "Caesarean section is a challenging intervention in patients treated with dual antiplatelet therapy. We present a case of a 32-year-old pregnant woman experiencing large acute myocardial infarction (MI) of the anterolateral wall, complicated by cardiogenic shock in the 38th week of pregnancy, and treated with drug-eluting stent implantation and dual antiplatelet therapy (DAPT) consisting of aspirin and ticagrelor. Less than 24 h after the MI delivery started, an urgent Caesarean section was indicated. As multiplate aggregometry testing showed a relatively insufficient level of ticagrelor platelet inhibition and a moderate level of aspirin platelet inhibition, a Caesarean section was performed without discontinuation of ticagrelor, which was decided due to the need for emergency surgery. Local hemostatic measures including administration of tranexamic acid were applied. The patient did not experience excessive bleeding. A healthy male baby was born. To the best of our knowledge, this is the first reported case of surgery in pregnant women treated with DAPT without ticagrelor discontinuation.",
publisher = "MDPI",
journal = "Journal of Personalized Medicine",
title = "Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention",
volume = "13",
number = "9",
doi = "10.3390/jpm13091344"
}

Antonijević, N., Mitrović, P., Gošnjić, N., Orlić, D., Kadija, S., Ilić Mostić, T., Savić, N., Birovljev, L., Leković, Ž.,& Matić, D.. (2023). Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention. in Journal of Personalized Medicine
MDPI., 13(9).
https://doi.org/10.3390/jpm13091344

Antonijević N, Mitrović P, Gošnjić N, Orlić D, Kadija S, Ilić Mostić T, Savić N, Birovljev L, Leković Ž, Matić D. Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention. in Journal of Personalized Medicine. 2023;13(9).
doi:10.3390/jpm13091344 .

Antonijević, Nebojša, Mitrović, Predrag, Gošnjić, Nikola, Orlić, Dejan, Kadija, Saša, Ilić Mostić, Tanja, Savić, Nebojša, Birovljev, Ljubica, Leković, Žaklina, Matić, Dragan, "Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention" in Journal of Personalized Medicine, 13, no. 9 (2023),
https://doi.org/10.3390/jpm13091344 . .

TY  - JOUR
AU  - Antonijević, Nebojša
AU  - Živković, Ivana D.
AU  - Jovanović, Ljubica M.
AU  - Matić, Dragan
AU  - Kocica, Mladen J.
AU  - Mrdović, Igor
AU  - Kanjuh, Vladimir
AU  - Ćulafić, Milica
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2783
AB  - Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug's efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug's safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Drug Metabolism
T1  - Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions
VL  - 18
IS  - 7
SP  - 622
EP  - 635
DO  - 10.2174/1389200218666170427113504
ER  - 

@article{
author = "Antonijević, Nebojša and Živković, Ivana D. and Jovanović, Ljubica M. and Matić, Dragan and Kocica, Mladen J. and Mrdović, Igor and Kanjuh, Vladimir and Ćulafić, Milica",
year = "2017",
abstract = "Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug's efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug's safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Drug Metabolism",
title = "Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions",
volume = "18",
number = "7",
pages = "622-635",
doi = "10.2174/1389200218666170427113504"
}

Antonijević, N., Živković, I. D., Jovanović, L. M., Matić, D., Kocica, M. J., Mrdović, I., Kanjuh, V.,& Ćulafić, M.. (2017). Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. in Current Drug Metabolism
Bentham Science Publ Ltd, Sharjah., 18(7), 622-635.
https://doi.org/10.2174/1389200218666170427113504

Antonijević N, Živković ID, Jovanović LM, Matić D, Kocica MJ, Mrdović I, Kanjuh V, Ćulafić M. Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions. in Current Drug Metabolism. 2017;18(7):622-635.
doi:10.2174/1389200218666170427113504 .

Antonijević, Nebojša, Živković, Ivana D., Jovanović, Ljubica M., Matić, Dragan, Kocica, Mladen J., Mrdović, Igor, Kanjuh, Vladimir, Ćulafić, Milica, "Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions" in Current Drug Metabolism, 18, no. 7 (2017):622-635,
https://doi.org/10.2174/1389200218666170427113504 . .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Trifunović, Danijela
AU  - Majkić-Singh, Nada
AU  - Ignjatović, Svetlana
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Marinković, Jelena
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1752
AB  - Objectives: To analyze the prognostic value of myeloperoxidase (MPO) in relation to in-hospital mortality and to identify the optimum time point for sampling in patients with the first anterior ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Design and methods: A total of 100 consecutive patients with the first anterior STEMI undergoing pPCI were included. Blood samples were collected at baseline, 4, 8, 12, 18, 24,48 and 168 hours (h) after pPCI. Results: MPO concentrations have showed a biphasic pattern over time; the highest MPO levels were at 4 h and 2411 after pPCI. In-hospital mortality was 6%. MPO at 24 h significantly correlated with troponin I as well as heart failure. After multivariate adjustment, MPO at 24 h was an independent predictor of the in-hospital mortality (OR 3.34, 95% CI 1.13-9.86, P = 0.029). Conclusions: In patients with the first anterior STEMI treated by pPCI. MPO at 24 h after procedure was an independent predictor of the in-hospital mortality.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
VL  - 45
IS  - 7-8
SP  - 547
EP  - 551
DO  - 10.1016/j.clinbiochem.2012.02.015
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Trifunović, Danijela and Majkić-Singh, Nada and Ignjatović, Svetlana and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Marinković, Jelena and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Objectives: To analyze the prognostic value of myeloperoxidase (MPO) in relation to in-hospital mortality and to identify the optimum time point for sampling in patients with the first anterior ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Design and methods: A total of 100 consecutive patients with the first anterior STEMI undergoing pPCI were included. Blood samples were collected at baseline, 4, 8, 12, 18, 24,48 and 168 hours (h) after pPCI. Results: MPO concentrations have showed a biphasic pattern over time; the highest MPO levels were at 4 h and 2411 after pPCI. In-hospital mortality was 6%. MPO at 24 h significantly correlated with troponin I as well as heart failure. After multivariate adjustment, MPO at 24 h was an independent predictor of the in-hospital mortality (OR 3.34, 95% CI 1.13-9.86, P = 0.029). Conclusions: In patients with the first anterior STEMI treated by pPCI. MPO at 24 h after procedure was an independent predictor of the in-hospital mortality.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention",
volume = "45",
number = "7-8",
pages = "547-551",
doi = "10.1016/j.clinbiochem.2012.02.015"
}

Stanković, S., Ašanin, M., Trifunović, D., Majkić-Singh, N., Ignjatović, S., Mrdović, I., Matić, D., Savić, L., Marinković, J., Ostojić, M.,& Vasiljević, Z.. (2012). Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 45(7-8), 547-551.
https://doi.org/10.1016/j.clinbiochem.2012.02.015

Stanković S, Ašanin M, Trifunović D, Majkić-Singh N, Ignjatović S, Mrdović I, Matić D, Savić L, Marinković J, Ostojić M, Vasiljević Z. Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. in Clinical Biochemistry. 2012;45(7-8):547-551.
doi:10.1016/j.clinbiochem.2012.02.015 .

Stanković, Sanja, Ašanin, Milika, Trifunović, Danijela, Majkić-Singh, Nada, Ignjatović, Svetlana, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Marinković, Jelena, Ostojić, Miodrag, Vasiljević, Zorana, "Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention" in Clinical Biochemistry, 45, no. 7-8 (2012):547-551,
https://doi.org/10.1016/j.clinbiochem.2012.02.015 . .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Majkić-Singh, Nada
AU  - Ignjatović, Svetlana
AU  - Mihailović, Mirjana
AU  - Nikolajević, Ivica
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Marinković, Jelena
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1701
AB  - Background: The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEM I) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI. Methods: Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (>= 840 pmol/L, n = 65) and low M PO group ( lt 840 pmol/L, n = 124). Results: The high M PO group had significantly more frequent anterior wall infarctions (p lt 0.001) and Killip class >1 on admission (p=0.013) as well as lower left ventricular ejection fraction (LVEF) (p=0.011) and higher B-type natriuretic peptide (BNP) (p=0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high M PO group (13.8%) than in the low MPO group (1.6%) (p=0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95%CI 1.13 - 13.34, p=0.031). Conclusions: Plasma M PO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI. (Clin. Lab. 2012;58:125-131)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
VL  - 58
IS  - 1-2
SP  - 125
EP  - 131
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1701
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Majkić-Singh, Nada and Ignjatović, Svetlana and Mihailović, Mirjana and Nikolajević, Ivica and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Marinković, Jelena and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Background: The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEM I) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI. Methods: Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (>= 840 pmol/L, n = 65) and low M PO group ( lt 840 pmol/L, n = 124). Results: The high M PO group had significantly more frequent anterior wall infarctions (p lt 0.001) and Killip class >1 on admission (p=0.013) as well as lower left ventricular ejection fraction (LVEF) (p=0.011) and higher B-type natriuretic peptide (BNP) (p=0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high M PO group (13.8%) than in the low MPO group (1.6%) (p=0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95%CI 1.13 - 13.34, p=0.031). Conclusions: Plasma M PO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI. (Clin. Lab. 2012;58:125-131)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention",
volume = "58",
number = "1-2",
pages = "125-131",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1701"
}

Stanković, S., Ašanin, M., Majkić-Singh, N., Ignjatović, S., Mihailović, M., Nikolajević, I., Mrdović, I., Matić, D., Savić, L., Marinković, J., Ostojić, M.,& Vasiljević, Z.. (2012). The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 58(1-2), 125-131.
https://hdl.handle.net/21.15107/rcub_farfar_1701

Stanković S, Ašanin M, Majkić-Singh N, Ignjatović S, Mihailović M, Nikolajević I, Mrdović I, Matić D, Savić L, Marinković J, Ostojić M, Vasiljević Z. The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory. 2012;58(1-2):125-131.
https://hdl.handle.net/21.15107/rcub_farfar_1701 .

Stanković, Sanja, Ašanin, Milika, Majkić-Singh, Nada, Ignjatović, Svetlana, Mihailović, Mirjana, Nikolajević, Ivica, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Marinković, Jelena, Ostojić, Miodrag, Vasiljević, Zorana, "The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention" in Clinical Laboratory, 58, no. 1-2 (2012):125-131,
https://hdl.handle.net/21.15107/rcub_farfar_1701 .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Trifunović, Danijela
AU  - Majkić-Singh, Nada
AU  - Miljković, Aleksandar
AU  - Ignjatović, Svetlana
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1687
AB  - Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt  463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p  lt  0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
VL  - 58
IS  - 11-12
SP  - 1135
EP  - 1144
DO  - 10.7754/Clin.Lab.2012.111102
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Trifunović, Danijela and Majkić-Singh, Nada and Miljković, Aleksandar and Ignjatović, Svetlana and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt  463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p  lt  0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention",
volume = "58",
number = "11-12",
pages = "1135-1144",
doi = "10.7754/Clin.Lab.2012.111102"
}

Stanković, S., Ašanin, M., Trifunović, D., Majkić-Singh, N., Miljković, A., Ignjatović, S., Mrdović, I., Matić, D., Savić, L., Ostojić, M.,& Vasiljević, Z.. (2012). Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 58(11-12), 1135-1144.
https://doi.org/10.7754/Clin.Lab.2012.111102

Stanković S, Ašanin M, Trifunović D, Majkić-Singh N, Miljković A, Ignjatović S, Mrdović I, Matić D, Savić L, Ostojić M, Vasiljević Z. Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory. 2012;58(11-12):1135-1144.
doi:10.7754/Clin.Lab.2012.111102 .

Stanković, Sanja, Ašanin, Milika, Trifunović, Danijela, Majkić-Singh, Nada, Miljković, Aleksandar, Ignjatović, Svetlana, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Ostojić, Miodrag, Vasiljević, Zorana, "Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention" in Clinical Laboratory, 58, no. 11-12 (2012):1135-1144,
https://doi.org/10.7754/Clin.Lab.2012.111102 . .